Lifevantage (NASDAQ:LFVN) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Lifevantage Corporation (NASDAQ:LFVN) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.04 and traded as low as $4.71. Lifevantage shares last traded at $4.96, with a volume of 923,481 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on LFVN shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a report on Friday, March 27th. Lake Street Capital reissued a “buy” rating on shares of Lifevantage in a research note on Thursday, February 5th. Finally, Loop Capital set a $5.00 target price on Lifevantage in a research note on Thursday, February 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

Lifevantage Stock Up 1.2%

The stock’s 50-day moving average price is $4.64 and its 200-day moving average price is $6.04. The company has a market capitalization of $63.54 million, a price-to-earnings ratio of 8.27 and a beta of 0.36.

Lifevantage (NASDAQ:LFVN) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.07). Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. The company had revenue of $48.93 million during the quarter, compared to analyst estimates of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS. On average, equities research analysts anticipate that Lifevantage Corporation will post 0.65 EPS for the current year.

Lifevantage Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 16th. Stockholders of record on Monday, March 2nd were paid a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 3.6%. The ex-dividend date of this dividend was Monday, March 2nd. Lifevantage’s dividend payout ratio (DPR) is 30.00%.

Insider Activity at Lifevantage

In other news, Director Judd Dayton bought 10,500 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was bought at an average price of $4.53 per share, for a total transaction of $47,565.00. Following the completion of the transaction, the director directly owned 80,359 shares in the company, valued at $364,026.27. The trade was a 15.03% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders acquired 38,207 shares of company stock valued at $178,585. 21.95% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lifevantage

Several hedge funds have recently added to or reduced their stakes in LFVN. JPMorgan Chase & Co. increased its position in Lifevantage by 870.2% in the second quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after purchasing an additional 4,499 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Lifevantage during the 2nd quarter valued at about $76,000. BNP Paribas Financial Markets boosted its stake in shares of Lifevantage by 2,555.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,135 shares of the company’s stock valued at $80,000 after purchasing an additional 5,904 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Lifevantage in the 1st quarter valued at about $97,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Lifevantage during the 2nd quarter worth approximately $102,000. Institutional investors own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.